Serene, LLC, is a privately held company that develops and commercializes radiolabeled diagnostic and therapeutic products for rheumatologic, arthritic, cardiovascular, and oncologic conditions in both human and veterinary medicine using conversion electron therapy. Serene was founded in 2014 and is headquartered near Houston in The Woodlands, Texas. The use of tin-117m (Sn-117m) as a medical isotope was initially developed by Dr. Suresh Srivastava at Brookhaven National Laboratory beginning over thirty years ago.
Tin-117m provides a platform for conjugation with any targeting molecule whose receptor is associated with cells or tissue that is to be destroyed. Tin-117m has already demonstrated safety in 135 human oncology and cardiovascular subjects, and is commercialized as Synovetin-OATM by Exubrion Inc., a spin-out of Serene. Our current applications include a homogeneous tin-117m colloid used in clinical trials for osteoarthritis and rheumatoid arthritis commencing in 2019, as well as products in development for prostate cancer, bone metastases, pancreatic cancer, and vulnerable plaque.